INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript

INmune Bio (INMB) reported a Q3 2025 net loss of $6.5 million, with a cash runway extending into Q4 2026, as it progresses multiple clinical programs. The company plans to submit CORDStrom for UK marketing authorization in mid-2026, followed by a US BLA, after its systemic RDEB treatment demonstrated significant clinical benefits in trials. For its Alzheimer's candidate, XPro, positive Phase II MINDFuL trial data in patients with high inflammation have been submitted for publication, and INmune Bio expects crucial FDA feedback on an accelerated pathway and end-of-Phase II meeting minutes in Q1 2026. Additionally, INKmune successfully completed its Phase II prostate cancer trial, meeting primary endpoints and setting the stage for a randomized Phase II design in 2026.

Analysis

INmune Bio (INMB) reported a Q3 2025 net loss of $6.5 million, a notable reduction from $12.1 million in Q3 2024, supported by decreased R&D expenses. With $27.7 million in cash, the company projects a runway into Q4 2026, critical for advancing its pipeline. CORDStrom, the most advanced program, is on track for a U.K. marketing authorization application (MAA) in mid-2026 and a U.S. Biologics License Application (BLA) by year-end 2026, with FDA feedback expected mid-2027.

The Phase II MissionEB trial for CORDStrom in RDEB demonstrated significant and safe benefits, including reduced itch and improved disease activity scores across over 30 children, with no severe adverse reactions. Management emphasizes CORDStrom's systemic effect and cost-effective manufacturing as key differentiators, positioning it as a potential first-in-class systemic treatment for RDEB, addressing a critical unmet need beyond topical gene therapies.

For XPro, INmune Bio anticipates an end-of-Phase II FDA meeting in Q1 2026 to discuss an accelerated pathway for Alzheimer's, focusing on EMACC and enrichment biomarkers. Phase II MINDFuL trial data, submitted for publication, showed positive results in highly inflamed patients, with expected Q4 2025 MRI data to further support its disease-modifying potential without ARIA safety signals. INKmune successfully completed its Phase II prostate cancer trial, meeting primary and two secondary endpoints, with plans for a randomized Phase II design in 2026.

Key Decisions for Investors

• Monitor the upcoming regulatory milestones for CORDStrom, specifically the U.K. MAA and U.S. BLA filings in 2026, as these represent significant value inflection points.
• Pay close attention to the FDA's feedback on XPro's accelerated pathway and the end-of-Phase II meeting minutes in Q1 2026, as this will define the path forward for its Alzheimer's program and potential partnerships.
• Evaluate the company's cash burn relative to its Q4 2026 runway, considering the capital intensity of late-stage clinical development and potential need for further financing or partnerships, particularly for XPro and INKmune's next phases.
• Assess the competitive landscape for RDEB, noting CORDStrom's systemic approach and cost advantages against existing topical gene therapies, which could influence market penetration and reimbursement.